U.S., Sept. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07797218) titled 'Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC' on Aug. 14.
Brief Summary: This is a randomized, open-label, superiority, multicenter clinical trial for patients with early or locally advanced (T>=2cm, N0-3, M0) HER2-positive breast cancer. It aims to compare the efficacy of neoadjuvant treatment with 2 cycles of Pyrotinib + Trastuzumab + Docetaxel followed by 2 cycles of Pertuzumab + Trastuzumab + Docetaxel versus 4 cycles of Pertuzumab + Trastuzumab + Docetaxel. Exploratory analyses of ctDNA clearance rate and MRI response will also be conducted.
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Breast Cancer E...